<DOC>
	<DOCNO>NCT01337310</DOCNO>
	<brief_summary>Tesetaxel orally active tubulin-binding inhibitor taxane class . Evaluation tesetaxel Japanese patient limited . This study conduct determine maximum tolerate dose safety tesetaxel administer orally every 21 day Japanese patient .</brief_summary>
	<brief_title>Study Tesetaxel Japanese Patients With Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Primary inclusion criterion : At least 20 year age Morphologic cytologic confirmation advance metastatic solid tumor malignancy , include lymphoma , standard therapy exist resistance intolerance standard therapy develop ECOG performance status 1 Adequate bone marrow , hepatic , renal function Willing remain hospitalized least 10 day follow tesetaxel administration Cycle 1 At least 4 week recovery effect prior surgery therapy approve investigational agent , resolution toxicity Grade 1 Primary exclusion criterion : Brain metastasis leptomeningeal disease Significant medical disease cancer Neuropathy great Grade 1</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Advanced solid tumor</keyword>
</DOC>